Zealand Pharma A/S

Equities

ZEAL

DK0060257814

Biotechnology & Medical Research

Market Closed - Nasdaq Copenhagen 10:59:34 2024-04-19 am EDT 5-day change 1st Jan Change
583.5 DKK -2.42% Intraday chart for Zealand Pharma A/S -1.02% +56.35%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
U.S. Futures Up, European Stocks Flat as Powell Reiterates Room for Rate Cuts This Year DJ
Zealand Pharma A/S Approves Appointments to the Board CI
Global markets live: Robinhood, Dollar General, KKR, Boeing, Oracle... Our Logo
Zealand Pharma A/S Announces Board Changes CI
Nordic Stocks Dropped Monday; Zealand Pharma Took Biggest Hit DJ
Nordic Stocks Moved Upward Thursday; Zealand Pharma Topped Leaders DJ
US Futures, European Stocks Mostly Down DJ
Drugmakers deepen efforts to tap into booming market for obesity drugs RE
Transcript : Zealand Pharma A/S, 2023 Earnings Call, Feb 27, 2024
US Futures Flat, European Stocks Mostly Rise DJ
Zealand Pharma A/S Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Zealand Pharma Shares Surge 41% on 'Positive' Results From Phase 2 Study of Weight Loss Drug Survodutide MT
Nordic Shares Declined Monday; Embracer Group Series B Posted Biggest Loss DJ
European Equities Close Mostly Lower in Monday Trading; UK Regulator Probes Homebuilders for Anti-Competitive Practices MT
Boehringer eyes obesity, fatty liver drug launch in 2027 or 2028 RE
BOEHRINGER EXEC BROUILLON TELLS REUTERS IT IS NOT CLEAR YET WHET… RE
Zealand Pharma: positive results in NASH CF
Commodity-linked stocks drag European equities lower RE
Zealand shares surge on liver drug data from Boehringer pact RE
Zealand Pharma shares surge on liver disease drug trial data RE
US Futures, European Stocks Mostly Fall DJ
Zealand Pharma A/S Announces Boehringer Ingelheim Survodutide Phase 2 Trial Shows 83% of Adults Treated a Statistically Significant Improvement of Metabolic Dysfunction-Associated Steatohepatitis CI
Nordic Shares Rose Monday; Vitrolife Topped Leaders DJ
Zealand Pharma, a new competitor for Novo Nordisk? Our Logo
Weight loss drug windfall attracts pharma companies RE
Chart Zealand Pharma A/S
More charts
Zealand Pharma A/S is specialized in the research and development of peptide drugs mainly for the treatment of diabetes, rare diseases and obesity. At the end of 2022, the Group had a portfolio of 7 products in clinical development (including 2 in phase III, 3 in phase II and 2 in phase I), and 4 products in preclinical development.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
583.5 DKK
Average target price
754.3 DKK
Spread / Average Target
+29.27%
Consensus
  1. Stock Market
  2. Equities
  3. ZEAL Stock
  4. News Zealand Pharma A/S
  5. Zealand Pharma Seeks DKK1.45 Billion from Private Placement